Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WP1066 in Pediatric Refractory/Recurrent Malignant Brain Tumors
NCT04334863Phase 1Completed
- Sponsor
- Emory University
- Start
- May 2020
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of WP1066 in brain tumor, medulloblastoma, malignant glioma and 4 more, sponsored by Emory University. Primary endpoints: Maximum Tolerated Dose and Dose Limiting Toxicities. Started May 2020; status: completed.
02
Drugs
WP1066
03
Conditions
brain tumormedulloblastomamalignant gliomadiffuse intrinsic pontine glioma (DIPG)diffuse midline glioma (DMG)
Beyond the preview
Go deeper on NCT04334863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04334863.